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The aim of this study was to investigate, if anhedonia, a salient component of depression, shows 
similar response patterns to neurotransmitter challenge tests as depression, and if the two ques-
tionnaire based components Physical (PA) and Social (SA) Anhedonia can be discriminated by dif-
ferences in drug related size and time of cortisol responses elicited by the specific serotonin (5- 
HT) and noradrenaline (NA) reuptake inhibitors citalopram and reboxetine and prolactin re-
sponses to the dopamine (DA) agonist bromocriptine orally applied to 36 male volunteers in a 
double blind balanced cross-over design. Analyses of variance applied to placebo corrected hor-
mone responses revealed that low and late DA responses were characteristics of global Depres-
sion and of Physical Anhedonia, and that low DA responses were associated with high NA re-
sponses in PA, and with low 5-HT responses in SA. These patterns were explained by differences in 
transmitter production and receptor sensitivities and proved to be suitable to discriminate PA 
from SA and from global depression by analysing neurochemical response patterns rather than 
single means of variables. 
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chopathological symptoms and states than relying on single biological markers. This also refers to identifying 
individual differences in Psychology and is not restricted to neurophysiological biomarkers but can also be ap-
plied to biochemical characterisation of individuals. In Psychiatry, the so called neurotransmitter challenge tests 
have frequently been applied for detecting disturbances in synthesis or release of the neurotransmitters nor- 
adrenalin, serotonin or dopamine as underlying biological mediators of psychiatric disturbances (e.g. review by 
Hasler et al., 2004). This is achieved by applying drugs that inhibit or stimulate the activity of these transmitters in 
the brain which leads to changes in release of hormones from the pituitary and adrenal cortex that can be measured 
in plasma and may serve as indicators of respective neurotransmitter abnormalities (see van de Kar, 1998). 
Particularly in affective disorders abnormalities in response to neurotransmitter challenge tests have been in-
vestigated (e.g. review by Power & Cowen, 1992; Yatham & Steiner, 1993 for the serotonergic systems or re-
view by Coupland et al., 1992 for the noradrenergic system, and by Insel & Sievers, 1981 for the dopaminergic 
system). Depressed patients, for instance, have been reported to show blunted hormone responses to the 5-hy- 
droxy-tryptamine (5-HT) releaser d-fenfluramine (Cleare et al., 1996), the 5-HT-reuptake inhibitors citalopram 
(Mattos et al., 2006), or clomipramin (Anderson et al., 1992), as well as increased hormone responses to stimu-
lation of the noradrenertgic system (NA), e.g., by the alpha2 receptor agonist clonidine (Charney et al., 1982; 
Lesch et al., 1988) or the noradrenaline reuptake inhibitor reboxetine (Schüle et al., 2004). Depressed patients 
also have been shown to exhibit low dopaminergic activity (Boadie et al., 2007) indicated e.g. by abnormal re-
sponses to dopamine agonists like apomorphine (Pitchot et al., 1992; Dailly et al., 2004; Stein, 2008). 
Several psychiatric disturbances, like anxiety or impulse control disorders and depression, have been shown 
to represent the end of a continuum from the normal range of personality characteristics into psychopathology 
(Eysenck, 1967; Pukrop et al., 2000; Livesley, 1998; Widiger, 2011). This can not only be demonstrated by an 
overlap between questionnaire scores on psychopathological symptoms observed in healthy samples and in 
clinical groups, but also has been demonstrated for neurotransmitter challenge tests applied to characterize re-
spective personality traits (e.g. Bond, 2001; Hennig & Netter, 2005). Healthy volunteers scoring high on depres-
sion related traits, for example, could be shown to resemble depressed patients in their responses to serotonergic 
stimulation by citalopram (e.g. Lotrich et al., 2005), or by clomipramine (Ruegg et al., 1997; Gerra et al., 2000). 
Similarly, increased cortisol responses to the noradrenaline reuptale inhibitor reboxetine in depressive healthy 
persons mirrored the effect of a noradrenergic challenge observed in depressed patients (Hennig et al., 2000), 
and a challenge by the dopamine D2 receptor agonist bromocriptine in healthy persons confirmed decreased 
dopaminergic activity observed in patients (Netter, 2006). 
But these findings cannot always be replicated in different samples and at different time points. Inconsisten-
cies in relating psychiatric symptoms or personality dimensions to neurotransmitter responses may partly derive 
from focusing merely on a single transmitter system at a time in the same population or sample instead of inves-
tigating constellations of transmitter responsiveness. Since neurotransmitter systems considerably influence each 
other and imbalance between systems has often been claimed to underlie psychiatric disturbances (Riederer & 
Birkmayer, 1980), it is essential to assess the sensitivities of different transmitter systems and their interactions 
in the same individuals as to identify neurochemical specificity of depression subtypes. 
One of the salient symptoms of depression is anhedonia (Stein, 2008; Lemke, et al., 1999), which is charac-
terized by loss of interests and of enjoyment of previous activities (Snaith, 1993; Nakonezny et al., 2010; Gutko- 
vich et al., 2011). It can also be observed in animals showing reduced motor activity and consumption of food 
after exposure to chronic mild stress (Willner, 1995, 2005) and could be shown to be associated with low dopa-
minergic activity in the mesolimbic system (Papp et al., 1994). So one of the hypotheses would be that a deficit 
of dopaminergic activity should become evident in anhedonia assessed in healthy humans as well. 
According to Chapman et al. (1976) two sub-dimensions of anhedonia have been identified by factor analysis 
which form the subscales of their Anhedonia Scale: Physical Anhedonia (PA) means not being susceptible to 
rewards by any kind of sensory stimuli (visual, acoustic, tactile, gustatory, movement), Social Anhedonia (SA) 
means being rather by oneself than with others and not taking interest in social activities: Although both aspects 
refer to loss of the ability to enjoy and to withdrawal from previously rewarding activities, they might represent 
different aspects of depression. So it is worthwhile to ask, if the two factors of anhedonia can be discriminated 
by their patterns of transmitter responsiveness, and if they are associated with patterns different from those 
linked to the larger concept of depression  
Besides the size of hormone responses to transmitter related challenge tests, the time the hormone takes to re-
spond to pharmacological stimulation has been shown to be a relevant variable for discriminating different types 
of receptor sensitivities (Depue et al., 1994; Netter et al., 2004; Netter, 2006). 
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So the major questions to be investigated by the present study are: 
1) Can Physical and Social Anhedonia be discriminated by differences in response patterns to pharmacologi-
cal challenges by dopaminergic, serotonergic and noradrenergic substances and are these patterns different from 
responses characteristic of global depression? 
2) Can time and size of hormone responses contribute differently to the discrimination between depression, 
Physical and Social Anhedonia? 
2. Method 
2.1. Subjects 
A sample of 36 male students (18 - 35 years) selected according to a health questionnaire on a separate day par-
ticipated in the experiment. Exclusion criteria were endocrinological, allergic, or cardiovascular diseases, pre-
vious or present neurological or psychiatric symptoms or psychotherapy, any drugs used as medication for the 
diseases mentioned above and body mass index > 26. The subjects signed informed consent and were instructed 
about data protection and told that they could leave the experiment any time. They were also requested to report 
any kind of side-effects to the experimenter. After completion of all our sessions (see below) they were re-
warded by 200 Euro. 
The study was approved by the Ethics Committee of the German Psychological Association. 
2.2. Design and Medication 
Participants were subjected to a double blind fourfold balanced cross-over design based on oral intake of the se-
rotonin (5-HT) reuptake inhibitor citalopram (Cit., 30 mg), the noradrenaline (NA) reuptake inhibitor reboxetine 
(Reb., 2 mg), the dopamine (DA) D2-agonist bromocriptine (Bromo., 1.25 mg) and placebo (Plac) at one week 
intervals performed at the same time of day. 
2.3. Procedure and Questionnaires 
On experimental days blood sampling for determination of hormones was achieved from an indwelling cannula 
which was inserted into the antecubital vein of the non-dominant arm at 12.15 p.m., followed by a standard meal 
of ≈ 700 kcal. Then participants filled in the Anhedonia Scale by Chapman et al. (1976) (see above: 84 items 
based on a dichotomous yes/no score; PA: 48 items, reliability: Cronbach’s alpha: 0.84; SA: 40 items, Cron-
bachs alpha: 0.78) and the Depression Scale by von Zerssen & Koeller (1976) (16 items scored by a four point 
Likert scale and related to symptoms of clinical depression like negative effect, lack of drive and psychosomatic 
symptoms). After administration of the drug at 3.00 p.m. baseline blood sampling took place and was continued 
at ½ hour intervals until 7 p.m. (10 samples). Blood was drawn through a dark rubber tube leading through the 
wall to an adjacent room so that participants were unaware of the time of blood sampling. 
2.4. Measurement of Hormones  
Since most transmitter related substances elicit cortisol as well as growth hormone and prolactin responses 
(Hennig & Netter, 2005), these three hormones were measured in the present experiment as responses to each of 
the three substances and placebo. However, the hormones cortisol as an indicator of the response to the seroto-
nergic and the noradrenergic drug and prolactin as an indicator of the response to bromocriptine emerged to be 
the most reliable and sensitive indicators for responses to the specific challenge substances used, while growth 
homone responses to citalopram, reboxetine and bromocriptine seemed to be liable to produce artifacts and pro-
lactin response was not sensitive enough to citalopram and reboxetine. Blood samples were drawn in serum 
tubes (Sarstedt, Nuembrecht, Germany) and were kept at room temperature for 20 minutes prior to centrifuga-
tion (2000 g). Immediately afterwards, 1 ml of serum was removed and stored at −30 degrees C until assayed. 
For cortisol and prolactin, serum samples were thawed immediately prior to measurement which was performed 
with commercial enzyme immunoassays (DRG, Marburg, Germany). All samples were run in duplicate. Assay 
protocols were applied to a fully automated system (Labotech, Biochem, Freiburg, Germany) yielding highly 
precise measurements for cortisol and prolactin with intra- and inter-assay coefficients of variance lower than 
5% and 8%, respectively. 
P. Netter, J. Hennig 
 
 278 
2.5. Derivation of Variables 
In order to quantify interactions between time and size of hormone responses and between two different trans-
mitter responses, dichotomised size and time of hormone responses served as independent variables and the 
questionnaire scores as dependent variables. For obtaining size and time of responses, the following steps were 
taken: 1) Cortisol raw scores obtained with placebo at each time point were subtracted from respective values 
obtained with citalopram and reboxetine respectively. Similarly, prolactin raw scores obtained with placebo 
were subtracted from those obtained with bromocriptine (here large negative values would indicate high re-
sponses). 2) For comparison of cortisol and prolactin responses, both sets of values were transformed into z- 
scores for each time point based on means of the respective hormone responses across all time points of the total 
sample. 3) In these z-transformed curves representing differences between drug and placebo responses of hor-
mones across 10 time points the baseline value was subtracted from the highest peak (lowest value with prolac-
tin). 4) This measure was dichotomised yielding size of response with two groups scoring below and above 0.60 
standard deviations of the total group respectively. So scores ≤ 0.60 standard deviations (SD) were classified as 
low, those > 0.60 SD as high responders. Time of response was defined as the time point of peak cortisol re-
sponse to reboxetine and to citalopram, and time of initial decrease of prolactin after intake of bromocriptine. 
Early responders were defined as responding 90 min or less after drug intake and late responders as those res-
ponding later than 90 minutes after drug intake (Identical cut off points close to the median were possible due to 
very similar kinetics (t max and half lives) of the three drugs). 
2.6. Statistical Evaluation 
Two-factorial analyses of covariance were performed 1) for size of responses between pairs of dichotomized 
drug responses (Cit × Reb, Cit × Bromo, Reb × Bromo) as independent variables and the 3 questionnaire scores 
PA, SA and Depression as dependent variables; 2) for time and size of responses (2 levels each) within each of 
the three transmitter related drug condition. In both cases the covariates were: body mass index and number of 
cigarettes smoked, because smoking had not been used as an exclusion criterion and is liable to be associated 
with hormone responses as well as with the questionnaire scores. 
This strategy for evaluation was chosen, because hormone responses were partly not normally distributed and 
furthermore, the sample size was too small as to allow for multiple regressions with 6 independent variables 
(time and size of each drug related hormone response). The significance level was set at alpha = 0.05, but ten-
dencies of values p > 0.05 and p < 0.10 will also be reported. 
3. Results 
Results will be presented within each of the dependent variables first with respect to constellations of sizes of 
responses to pairs of drugs and then with respect to interactions of time and size of each single drug response. 
3.1. Global Depression 
Global depression scores were only marginally associated with the size of responses as can be seen from Figure 
1 showing the interaction between size of responses to citalopram and reboxetine (F1;33 = 3.71; p = 0.096). The 
combination of high noradrenergic and high serotonergic responses was associated with highest depression 
scores. No significant results or tendencies were obtained for the combined effects of citalopram and bromocrip-
tine or reboxetin and brocriptine.  
For the interaction between time and size of responses results only showed a significant effect for the dopa-
minergic drug (Figure 2): low and late prolactin responses to bromocriptine were particularly characteristic of 
persons scoring high on depression (interaction: (F1;33 = 5.24; p = 0.015). 
3.2. Physical Anhedonia (PA) 
Evaluation of reboxetine in combination with bromocriptine responses revealed that besides the main effects for 
each drug (F1;33 = 4.96; p = 0.027 for reboxetine and F1;33 = 7.56; p = 0.009 for bromocriptine) a significant in-
teraction (F1;33 = 5.22; p = 0.016) indicated that high PA was particularly pronounced in participants who 
showed high responses to reboxetine and low responses to bromocriptine, as shown in Figure 3. There were no  




Figure 1. Depression scores according to high and 
low responses to citalopram and and reboxetine. 
 
 
Figure 2. Depression scores according to size and 
time of responses to bromocriptine. 
 
 
Figure 3. Physical Anhedonia according to sizes 
of reboxetine and bromocriptine responses. 
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effects or interactions observed for responses to the serotonergic drug citalopram. 
Furthermore, low responses to bromocriptine were again associated with late onset of decrease of prolactin 
for participants high on PA as shown by the interaction of time and size of responses to bromocriptine (F1,33 = 
4.83; p = 0.026) in Figure 4. The cortisol responses to reboxetine of high PA participants, however, rather 
tended to occur within the first 90 minutes as indicated by a marginal difference between early and late res-
ponders , but without showing an interaction with size of cortisol responses (mean ± (SEM) in z-scores of PA: 
early responders: +0.233 (0.321), late responders: −0.384 (0.214), F1;33 = 3.86; p = 0.093). No time effects were 
observed for citalopram. 
3.3. Social Anhedonia (SA)  
Transmitter responses observed for Social Anhedonia differed from both Depression and PA: As shown in Fig-
ure 5: high SA was particularly characterized by a low citalopram response (main effect F1;33 = 7.43; p = 0.011) 
which became most pronounced when combined with a low response to bromocriptine (interaction F1;33 = 4.68; 
p = 0.030). No side effects were observed for reboxetine, and time effects did not become significant for any of 
the three drugs. 
3.4. In Summary 
The following significant relationships have been obtained for the three questionnaire scales regarding time and 
size of responses (Figure 6). 
 
 
Figure 4. Physical Anhedonia according to time 
and size of responses to bromocriptine. 
 
 
Figure 5. Social Anhedonia as related to size of 
responses to citalopram and bromocriptine. 




Figure 6. Summary of results for patterns of sig-
nificant transmitter response characterizing De-
pression, Physical and Social Anhedonia (DA = 
dopaminergic drug (bromocriptine), NA = nora-
drenergic drug (reboxetine), 5-HT = serotonergic 
drug (citalopram), + = high/late; − = low/early re- 
sponse; (+) (−) = tendencies; curved lines = inter- 
actions). 
 
High scorers on all three scales show low DA responses, but while Physical Anhedonia shares low and late 
DA responses with Global Depression, it is additionally characterized by the combination of low DA with high 
rather early occurring NA response, while in Social Anhedonia low DA response is associated with low 5-HT 
responses. 
4. Discussion 
Some limitations of the study have to be discussed as a prerequisite: The usefulness of challenge tests for inves-
tigating psychopathological traits may be questioned for two reasons: 1) hormone responses may not only rep-
resent transmitter function but also the sensitivity or disturbance of the hypothalamo-pituitary-adrenal (HPA) 
axis responsible for cortisol release or of the pituitary prolactin producing cells suppressed by the tuberoinfun-
dibular dopaminergic system. 2) Often it can not be decided, if a hormone response is due to dysfunction of 
transmitter production, release, receptor sensitivity, or transmitter metabolizing enzymes. The authors are aware 
that without additional tests for sensitivity of the endocrinological systems, the first point can not be clarified in 
our study, and answers to the second point can only be inferred from studies in clinical samples based on posi-
tron emission tomography (PET) or specific additional psychopharmacological experiments or on animal re-
search based on intracerebral biochemical analyses. Yet transmitter related challenge tests have frequently been 
used in patients for detecting subtypes or severity of the disease or for deciding on choice of treatment and pre-
dicting treatment response. Therefore the following discussions of our results have to be regarded as cautious 
interpretations, but yet as promising attempts to elucidate the biological basis of clinical symptoms by using 
healthy volunteers as models. 
Another drawback of the study may be the selection of male young persons, whose sex and age do not repre-
sent the features of patients suffering from depression. The inclusion of females would have destroyed the de-
sign, because hormone responses partly depend on the phase of the menstrual cycle (Arato & Bagby, 1998; 
O’Keane et al., 1991), which would have created unequal phases of measurement in the fourfold cross-over de-
sign. Furthermore, if results obtained in young healthy males are comparable to those obtained with the same 
challenge tests in an older predominantly female population of depressed patients, this would rather corroborate 
than obscure the relationships between transmitter related responses and depression related personality dimen-
sions. 
The results obtained for Global Depression confirm previous findings that low DA responses are characteris-
tic of depressed patients (Pitchot et al., 1992; Hansenne et al., 2002; Dailly et al., 2004), but beyond this, the 
combined effect of low and late responses also emphasises the finding published by Depue et al. (1994) that the 
time of the prolactin response to a bromocriptine challenge test may be as essential as its size. While a low size 
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of response could be due to low production of DA, the late decrease of prolactin could also be due to pharmaco-
kinetic factors in the periphery, like absorption and metabolism, but late or early responding to noradrenergic or 
serotonergic stimulation did not match the early versus late dopaminergic responses in our sample, so that ki-
netic causes in the periphery are unlikely. Since a higher density of DA receptors is found in the striatum of de-
pressed patients (Shah et al., 1997) indicating compensatory upregulation of DA receptors due to low DA pro-
duction, it may be conceived that it takes longer for the DA receptor agonist bromocriptine to obtain full recep-
tor occupancy. It has been shown by PET studies that clinical effects or any type of response to dopaminergic 
stimulation depend on receptor occupancy which again depends on availability of the transmitter (e.g. Nyberg et 
al., 1995), so that it takes longer to reach the critical level of occupancy.  
The combined high NA + high 5-HT response in depressive participants was only marginal. It may point to a 
common hyper-responsiveness of the HPA axis, since cortisol responses to the two transmitter related sub-
stances citalopram and reboxetin were significantly correlated (r = 0.378, p < 0.05) This could point to hyper-
sensitive receptors of the corticotropin releasing factor (CRF) typical for depression (Reul & Holsboer, 2002), 
but it may also demonstrate the close functional association of the two transmitters on the brain level (Hetzel et 
al., 2004; Mongeau et al., 1997). Furthermore, the concept of pharmacotherapy of depression by mixed 5-HT + 
NA reuptake inhibitors implies that both types of postsynaptic receptors may be upregulated due to low 5-HT 
and NA production in depression and therefore are both liable to pronounced hormone responses. 
Physical Anhedonia shares the low and late DA responses with global Depression confirming its close affin-
ity to depression. The pronounced NA response confirms results observed in depressive patients (Charney et al., 
1982) and in volunteers scoring high on a depression scale (Hennig et al., 2000). So the weak association found 
between Depression scores and NA response seems to be caused by the component of Physical Anhedonia and 
confirms the results reported by Shelton & Tomarken (2001) who claimed that anhedonia is characterized by a 
relationship to the NA and DA system as opposed to stress and anxiety. In our study high NA receptor sensitiv-
ity could also explain the fast onset of cortisol responses to reboxetine. 
Social Anhedonia shares low DA responses with Depression and Physical Anhedonia, which matches the 
molecular genetic finding that both Physical and Social Anhedonia were highest in relatives of schizophrenics 
who were homozygous for the val allel of the catechol-O-methyl-transeferase (COMT) gene (Docherty & 
Sponheim, 2008) which results in faster degradation of dopamine due to a higher activity of the COMT enzyme. 
But Social Anhedonia seems to differ from both Physical Anhedonia and Depression by low 5-HT responses. 
While Physical Anhedonia was only characterised by catecholaminergic responses, Social Anhedonia shows an 
affinity to the serotonergic system. Blunted responses to 5-HT related drugs are frequently observed in psycho-
paths and antisocial or impulsive persons who are supposed to suffer from low production of 5-HT (e.g. Asberg 
et al., 1976). This would mean that an uptake inhibitor like citalopram can not lead to a large increase of 5-HT in 
the synaptic cleft so that the low response of socially anhedonic persons could be explained by low production 
of 5-HT. The combination of low DA and low 5-HT responses resembles the pattern described for withdrawal 
induced anhedonia (Rothman et al., 2002) or the type of anhedonia described as negative symptoms in schizo-
phrenia with a predominance of social withdrawal (Wolf, 2006; Kuha et al., 2011; Juckel et al., 2003). It is con-
ceived as a fairly enduring trait (Cohen et al., 2011) with probably a hereditary component (Docherty & Spon-
heim, 2008). But it seemed worthwhile to investigate anhedonia also within the frame of depression, since 
transmitter responses induced by the challenge tests were able to discriminate the two components of anhedonia. 
These might represent the types of anhedonia encountered in depression versus in schizophrenia. In spite of a 
positive correlation between Physical and Social Anhedonia (r = 0.37, p < 0.05), Physical Anhedonia is more 
closely related to global Depression (r = 0.387, p < 0.05), whereas the correlation of Social Anhedonia with De-
pression is not significant. (r = 0.130, p > 0.10). 
5. Conclusion 
Although the causal mechanisms of hormone responses to neurotransmitter challenge tests performed in humans 
can not be directly assessed, challenge tests are proved to be suitable tools for discriminating two types of an-
hedonia and their relation to depression. This is the first study investigating anhedonia in a healthy sample by 
neurotransmitter response tests. These were able to show that on a biochemical level, Physical Anhedonia rep-
resented a core symptom of depression, but that Social Anhedonia might rather have an affinity to psychopatho-
logical syndromes characterised by the symptom of social withdrawal observed as a negative symptom in schi- 
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zophrenia. Moreover, it was demonstrated that the time of hormone responses, when combined with their sizes, 
could serve as a useful tool for detecting types of transmitter disturbances and that it is essential to investigate 
interactions of time and size of responses as well as of different transmitter responses when trying to elucidate 
characteristic patterns of specific traits or symptoms. These aspects should be considered in future challenge 
studies. Furthermore, the study indicates that healthy volunteers can serve as models for investigating the neuro-
biological basis of psychopathological dimensions.  
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